Telomir Announces New Research Findings From Ohio State University College Of Veterinary Medicine Showing Telomir-Zn Produces Inhibition Of Cell Growth Across Human And Canine Osteosarcoma Models
Telomir Pharmaceuticals, Inc. (NASDAQ:TELO), a clinical-stage biotechnology company developing small-molecule therapeutics targeting epigenetic and metabolic drivers of cancer, announced new research findings from The
Telomir's medicine stopped cancer cells from growing in lab tests. This is early research, so watch if the company moves toward human testing next.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.